NEW YORK, Sept. 29, 2016 /PRNewswire/ -- Pomerantz LLP is
investigating claims on behalf of investors of Seres Therapeutics,
Inc. ("Seres" or the "Company") (NASDAQ: MCRB) (ISIN:
US81750R1023). Such investors are advised to contact
Robert S. Willoughby at
rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether Seres and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
[Click here to join a class action]
On July 29, 2016, Seres issued a
press release announcing that the Phase 2 clinical trial of
SER-109, the Company's lead drug product candidate, did not achieve
its primary endpoint. In an earnings call, President and CEO
Roger J. Pomerantz also revealed
that certain undisclosed modifications had been made to the
formulation of SER-109 prior to the trial.
On these disclosures, Seres stock fell $26.04, or 72.8%, over the next two trading days,
to close at $9.73 on August 1, 2016.
The Pomerantz Firm, with offices in New York, Chicago, Los
Angeles, and Florida, is
acknowledged as one of the premier firms in the areas of corporate,
securities, and antitrust class litigation. Founded by the late
Abraham L. Pomerantz, known as the
dean of the class action bar, the Pomerantz Firm pioneered the
field of securities class actions. Today, more than 80 years later,
the Pomerantz Firm continues in the tradition he established,
fighting for the rights of the victims of securities fraud,
breaches of fiduciary duty, and corporate misconduct. The Firm has
recovered numerous multimillion-dollar damages awards on behalf of
class members. See www.pomerantzlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-shareholders-of-seres-therapeutics-inc--mcrb-300336973.html
SOURCE Pomerantz LLP